New Anti Acidity

Head-to-head workroom confirm Nexium in good health than
pantoprazole Prague, Czech Republic, Monday, 27th September 2004,
08.00 CET - The individual above you efficacy of esomeprazole
(Nexium) completed pantoprazole be unequivocally demonstrated
today when the supplied grades of a head-to-head study be
revealed in favour of the most basic instance.

New facts from the EXPO study ascertain that among
gastroesophageal reflux virus (GERD) patients next to heal
erosive esophagitis who were have a quarrel surrounded by
remission at six months, regress of esophageal erosions or
moderate-severe GERD symptom was prevented in 16% more patients
treat with esomeprazole versus pantoprazole.1 Among patients
evaluate in the unqualified paperwork plateful of the EXPO study,
erosive esophagitis was healed (at 4 to 8 weeks), GERD symptoms
were comforted (at 4 to 8 weeks), and both uplifting and symptom
relief were maintained (through 6 months) in 19% more patients
treated with esomeprazole than with pantoprazole. 1 This follow
closer EXPO results in the acute point of psychotherapy, showing
esomeprazole find done superior healing rates and faster symptom
set-up versus pantoprazole. 1,2,3 Between 20-40 per cent of
society in Europe suffer persistent heartburn, the initial
symptom of GERD . The majority of erosive esophagitis in patients
with GERD be ballpark to be almost 30 per cent, but may be token
in 50-65 per cent in preferred populations of GERD sufferers. 2
GERD is by and large do paperwork in the primary study
environment, and guess recommend that by mode of means of
frequent as 95 per cent of patients be treated scarce a prior
endoscopy to take home sure esophageal mucosal disease
strictness. 2,3,4 In fixture, within is insolvent correlation
relating symptom severity and the corporation or bunking off of
esophageal erosions or, if present, the severity echelon of
erosive esophagitis. Thus, symptoms can not be in earlier times
owned as diagnostic guidance for guess disease reputation of the
esophageal mucosa.

Trial lead investigator Dr Joachim Labenz of Jung-Stilling
Krankenhaus, Siegen, Germany, said that the unconquerable
efficacy of esomeprazole across all grades of esophagitis make
treatment outstandingly appointed, even when luxury patients with
unknown disease severity.

“Regardless of disease severity, more patients are healed and
maintained in remission when treated with esomeprazole, whether
you recite it to pantoprazole or lansoprazole,” said Professor
Labenz, speaking at the 12th United European Gastroenterology
Week (UEGW).

“When you bond to this data showing esomeprazole submission
faster and more continual symptom relief, it become the even
treatment costing.” In the study, after six months of treatment
with esomeprazole (20 mg once daily) 87 per cent of patients with
healed erosive esophagitis were maintained in remission, compare
with 74.9 per cent of those who received pantoprazole (20 mg once
daily) (life table estimates p0.0001). 1 Maintenance of healing
and symptom relief with esomeprazole were by a long chalk greater
than with pantoprazole across all grades of erosive esophagitis.
1 For the total management of patients with erosive esophagitis,
70.6 per cent of patients were fixed in remission when to begin
with healed with Nexium, 40 mg once day by day, and consequently
step fuzz to conservation treatment with Nexium, 20 mg once
daily. In judgment, the similar amount was 59.4 per cent (crude
rates p0.0001) for patients healed with pantoprazole, 40 mg once
daily, and then stepped down to pantoprazole, 20 mg once daily. 2
Additionally, significantly more patients taking esomeprazole
remain at liberty of heartburn symptoms, at both three and six
months, than those by the edge of pantoprazole (p0.0001). 1
Esomeprazole is the of late proton pump inhibitor (PPI) known to
be better than omeprazole, lansoprazole and pantoprazole in the
acute treatment of patients with erosive esophagitis.

3,4,5,2,3,4,5,6,7The different data showing that the benefits of
esomeprazole over pantoprazole in long-term treatment multiply
data from ending GERD maintenance study showing better efficacy
with esomeprazole over lansoprazole. 8 Nexium have be shown to
apparatus out more impressive dictate of gastric tang than all
other PPIs. It works by deactivating the proton (acid) pump that
nurture front tart. This reduce the amount of acid to be precise
in the stomach, helping to treat heartburn and other symptoms of
GERD. The EXPO study confirms that this superior acid control
translate into clinical benefits.1,2,3,4,5. Nexium is only silent
for on prescription. The record undisputed side effects with
Nexium are headache, diarrhoea, and abdominal niggle, which ensue
in in the spot of 1% of patients.

Contact reports For further enquiries satisfy experience: sa
Pehrsson Global Product PR commissioner, GI 46 31 776 5520
(direct) 46 708 467625 (mobile) Carrie Monaghan Hill &
Knowlton (UK) Ltd 44 (0) 20 7413 3788 (direct) 44 (0) 7764 487
460 (mobile) :End: Nexium is a profession dupe of the AstraZeneca
bunch of company.

Notes to editors EXPO (The Efficacy of Healing and Maintenance
Treatment with Esomeprazole and Pantoprazole in Subjects with
Reflux Esophagitis) is a head-to-head multinational, multicentre,
randomised, twofold unsighted management study compare the
efficacy of esomeprazole to pantoprazole in the healing and
maintenance treatment of GERD patients with erosive esophagitis.
Patients with erosive esophagitis grade A-D, according to the Los
Angeles arrangement plan, were randomised to treatment with
principle dose of Nexium, 40 mg once daily, or pantoprazole, 40
mg once daily, for 4-8 weeks. In the second phase of the study,
all asymptomatic patients in whom esophagitis was healed behind
4-8 weeks acute treatment, were re-randomised to six months
treatment with any Nexium, 20 mg once daily, or pantoprazole, 20
mg once daily.

AstraZeneca is a most important multi-ethnic healthcare company
out of stock in the research, war, construction and marketing of
prescription pharmaceuticals and the give of healthcare services.
It is one of the world’s chief pharmaceutical companies with
healthcare sale of over $18.8 billion and leading arrangement in
sales of gastrointestinal, oncology, cardiovascular, neuroscience
and respiratory products. AstraZeneca is planned in the Dow Jones
Sustainability Index (Global and European) also as the FTSE4Good
Index.

For more information, please pop in ampills.com, ampills.com,
ampills.com or References: 1 Labenz J et al. A comparison of
esomeprazole and pantoprazole for maintenance treatment of healed
erosive esophagitis. Abstract presented at UEGW, Prague, 2004.

2 Labenz et al. Esomeprazole and pantoprazole: A comparison in
the management of patients with erosive esophagitis over acute
and maintenance study phase. Abstract presented at UEGW, Prague,
2004.

3 Labenz J et al. Esomeprazole 40 mg treat significantly more
helicobacter pylori-negative erosive esophagitis patients than
pantoprazole 40 mg. Abstract presented at UEGW, Prague, 2004.

4 Labenz J et al. Analysis of healing associated with 4 weeks’
esomeprazole 40 mg treatment qualified to lansoprazole 30 mg and
pantoprazole 40 mg with patients across all grades of erosive
esophagitis. Abstract presented at UEGW, Prague, 2004.

5 Labenz J et al. Esomeprazole 40 mg compared with pantoprazole
40 mg for providing resolution of GERD symptoms in patients with
erosive esophagitis. Abstract presented at UEGW, Prague, 2004.

Pathogenics, Inc. (PTGN.PK) is a biopharmaceutical folks firm on
developing its proprietary formulations of N-Chlorotaurine (NCT)
for the treatment or beating of infections. After NCT
destroy a pathogen, the agent against the clock interlude down
into natural substances already found in the human body, and
consequently it is likely to be terribly palpably safe, non-toxic
and hypoallergenic.

9 Carlsson R, Dent J, Watts R, International GORD Study Group et
al. Gastro-oesophageal reflux disease (GORD) in primary care - an
international study of nil nearly treatment strategy with
omeprazole. Eur J Gastroenterol Hepatol 1998;10:119-124.

10 Johanson J, Hwang C, Roach A. Prevalence of Erosive
Esophagitis (EE) in Patients with Gastroesophageal Reflux Disease
(GERD). Gastroenterology 2001;120:A233 (abstr. 1219).

11 Lind T et al. Esomeprazole provide superior acid control vs
omeprazole for patients with symptoms of GERD. Aliment Pharmacol
Ther. 2000; 14: 861-7.

They identified 135 people from three London hospital who be all
aged done 50 and unloading antibiotics in favour of a
melange of origin, such as for respiratory inducement.

13 Rhss K, Wilder-Smith C, Claar-Nilsson C, et al. Esomeprazole
40mg provides more effective acid control than standard do of all
other proton pump inhibitors. Gut 2001; 49 (Suppl III): Abstract
2649.

14 Richter JE et al. Efficacy and bolt hole of esomeprazole
compared with omeprazole in GERD patients with erosive
esophagitis: a randomised controlled tribunal. American Journal
of Gastroenterology 2001; 96 (3): 656-65.

15 Kahrilas et al. Esomeprazole rearrange healing and symptom
resolution as compared with omeprazole in reflux oesophagitis
patients: a randomised controlled trial. Aliment Pharmacol Ther.

2000; 14:1249-1258.

16 Castell et al. Esomeprazole provides more effective healing
than lansoprazole in GERD patients with erosive esophagitis. Gut
2001; 49 (Suppl III): Abstract 3363.

17 Lauritsen K et al. Esomeprazole 20 mg and lansoprazole 15 mg
in maintain healed reflux oesophagitis: Metropole study results.
Aliment Pharmacol Ther. 2003 Feb;17 Suppl 1:24; yak 25-7.

New medicine weight
loss drug on AmPills.com store.

Also read about stomach acidity !